Rexahn Pharmaceuticals Inc. | Ownership
Companies that own Rexahn Pharmaceuticals Inc.
The Vanguard Group, Inc.
1,100,434
3.47%
855
0%
06/30/2018
BlackRock Fund Advisors
183,533
0.57%
11,553
0%
06/30/2018
Geode Capital Management LLC
146,083
0.46%
0
0%
06/30/2018
Virtu Financial BD LLC
84,751
0.27%
84,751
0.01%
06/30/2018
Northern Trust Investments, Inc.
82,605
0.26%
5,392
0%
06/30/2018
Bridgeway Capital Management, Inc.
53,100
0.17%
0
0%
06/30/2018
Zürcher Kantonalbank (Investment Management)
34,767
0.11%
0
0%
06/30/2018
Wedbush Securities, Inc. (Investment Management)
25,500
0.08%
0
0.01%
06/30/2018
Hudson Valley Investment Advisors, Inc.
20,000
0.06%
0
0.01%
06/30/2018
Citadel Advisors LLC
16,722
0.05%
16,722
0%
06/30/2018
| Address |
15245 Shady Grove Road
Rockville Maryland 20850
United States
|
|
Employees
|
- |
| Website |
http://www.rexahn.com |
| Updated |
09/14/2018 |
| Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; RX-5902 or Supinoxin for metastatic triple negative breast cancer; and RX-0201 or Archexin for renal cell carcinoma, glioblastoma, ovarian, stomach, and pancreatic cancer. It also develops nano-based drug delivery systems. |
